Видео с ютуба High Risk Residual Disease

Early-Stage HER2+: Defining "High Risk" in Residual Disease

FAQs on High-Risk Disease

Why T-DXd Could Replace T-DM1 in High-Risk Patients

Depth of response and MRD status in ultra high-risk MM: Results of the UK optimum/MUKnine trial

The current role of CAR T-cell therapy in high-risk B-ALL

Prognosis and treatment in high-risk MDS

High-risk myeloma patients tend to relapse quickly, but aggressive treatment leads to good outcomes.

How Minimal Residual Disease and Genetics Guide Myeloma Care – Dr. Martin Kaiser

Treatment options for high-risk AML

Minimal residual disease: a key determinant of ALL treatment response

Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer

Do high risk patients do transplant immediately? #AML

The High Risk Patient

High-risk disease biology in multiple myeloma

Minimal Residual Disease (MRD) Study to Optimize Definition and Therapy of High-Risk Acute Lympho...

Therapy for High Risk NMIBC

Minimal Residual Disease (MRD) | High Impact Topic (HIT)

Updates on current research exploring treatment strategies for high-risk smoldering myeloma

Dr Linscott on the Need for Improved MRD Detection in High-Risk NMIBC

Treating ultra high risk myeloma patients in a unique UK study | Martin Kaiser, MD | ASH 2021